{
    "Trade/Device Name(s)": [
        "HemosIL Liquid Anti-Xa"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K223187",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN190032",
        "K213464"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QLU"
    ],
    "Summary Letter Date": "June 23, 2023",
    "Summary Letter Received Date": "May 24, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.7295"
    ],
    "Regulation Name(s)": [
        "Heparin And Direct Oral Factor Xa Inhibitor Drug Test System",
        "Anti-Factor Xa Activity Test System"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Unfractionated heparin (UFH)",
        "Low molecular weight heparin (LMWH)",
        "Apixaban",
        "Rivaroxaban"
    ],
    "Specimen Type(s)": [
        "Citrated human plasma"
    ],
    "Specimen Container(s)": [
        "3.2% sodium citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ACL TOP Family",
        "ACL TOP Family 50 Series"
    ],
    "Method(s)/Technology(ies)": [
        "Chromogenic assay"
    ],
    "Methodologies": [
        "Quantitative factor Xa activity measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL Liquid Anti-Xa automated chromogenic assay for quantitative determination of UFH, LMWH, apixaban, and rivaroxaban using ACL TOP analyzers",
    "Indications for Use Summary": "Automated chromogenic assay for quantitative measurement of UFH, LMWH, apixaban, and rivaroxaban in adult citrated plasma to aid in assessment of patients at risk for major bleeding or experiencing bleeding episodes, for prescription use only and to be interpreted with other clinical findings",
    "fda_folder": "Hematology"
}